NOF's Dividend Gets Bigger While Profits Dip - That's the Point of the Trade

The headline about NOF Corporation's profit decline is true. The part that matters more is that the company is raising its dividend to ¥70 per share while doing it.

If you're here because you want cash flow that compounds without needing a heroic stock price, the numbers behind that headline deserve a closer look. The profit dip is real but it's structural, not a credit event. The payout is well-covered, the balance sheet is fortress-grade, and the stock has pulled back roughly 20% from its 52-week high. That combination - intact income engine, lower entry price, room for buybacks - is the setup income investors should be paying attention to.

What Actually Happened

NOF's fiscal 2025 (ended March 2026) delivered record highs across the board. Net sales rose 8.2% to ¥257.97 billion, operating profit grew 4.6% to ¥47.4 billion, and profit attributable to owners of the parent jumped 11.1% to ¥40.55 billion. Earnings per share reached ¥176.3.

Then came the guidance for fiscal 2026, which is where the "profit decline" story originates. NOF is forecasting net sales of ¥319.0 billion - a 23.7% jump. Operating profit is expected to grow 5.5% to ¥50 billion. But net profit is guided to fall 3.8% to ¥39 billion, with EPS at ¥169.60.

The gap between revenue growth and profit growth is intentional. Management is pouring money into three growth engines: defense-related explosives (Japan is roughly doubling its defense budget through 2027), pharmaceutical formulation ingredients for drug delivery systems, and expanded capacity under its "NOF VISION 2030" mid-term plan. That plan calls for ¥93 billion in capital expenditure through fiscal 2028, alongside ¥96 billion or more in shareholder returns.

In plain English, NOF is choosing to reinvest now to grow the revenue base, accepting that net profit will compress in the near term. That is different from a company losing pricing power or facing a margin crisis. It is a company spending to build.

The Dividend Doesn't Care About Stock Price Drama

The annual dividend moved from ¥45 per share in fiscal 2024 to ¥61 in fiscal 2025 - a 36% increase. The forecast for fiscal 2026 is ¥70, another 15% step up.

Coverage is the real question. On fiscal 2025 earnings of ¥176.3 per share, the ¥61 dividend gave a payout ratio of 34.6%. Against the fiscal 2026 EPS guidance of ¥169.60, the ¥70 dividend implies a payout ratio of roughly 41%. That is higher, but still well inside the zone where a cut is avoidable. NOF has targeted a total return ratio (dividends plus buybacks) of around 50% under its current plan.

The company also authorized a ¥5 billion share buyback in May 2026, covering up to 1.7 million shares. Buybacks on a falling stock are a form of shareholder return that compounds the per-share value of future dividends.

Operating cash flow for fiscal 2025 came in at ¥35.87 billion - more than enough to cover the dividend of roughly ¥14.4 billion (¥61 per share on about 236 million shares). Cash flow, not accounting profit, is what actually funds the check.

The Balance Sheet Is the Real Safety Net

NOF's equity-to-asset ratio sits at 74.0%. For context, most industrial chemical companies run in the 30–50% range. A 74% equity ratio means debt and financial leverage are genuinely low. The company has total assets of ¥399.17 billion and net assets of ¥296,465 million.

Why this matters: if raw material costs spike, a customer segment softens, or the yen moves against the company's export mix, a highly leveraged company might cut the dividend to protect its credit. NOF doesn't have that problem. There is no debt overhang forcing a painful choice between the balance sheet and the payout.

Return on equity came in at 14.1% for fiscal 2025. Management's target is 14% or higher by 2028 and 15% or higher by 2030. If that plan plays out, the expanding revenue base and disciplined capex should lift profitability back toward those targets. That is the bridge story: invest now, expand margins later.

What's Weighing on the Stock

The stock has retreated about 20% from its 52-week high of ¥3,400, trading in the ¥2,749–2,812 range. It currently trades at roughly 14.57 times trailing earnings, near the lower end of its recent 17.35x four-quarter average. The pullback reflects a mix of factors: yen weakness making Japanese exports relatively more expensive, broad risk-off pressure on Tokyo small- and mid-cap names, and investor unease with the profit dip in guidance.

None of these factors directly attacks the dividend. Currency moves affect revenue translation, not the cash-flow engine's ability to pay ¥70 per share. Broad market sentiment is noise for an investor who is measuring progress in income collected, not screen color.

The Bear Case

The counterargument is straightforward: what if the growth investments don't pay off fast enough? Japan's defense buildup is a real tailwind, but government spending is subject to political and budget cycles. The pharmaceutical materials business benefited enormously from COVID-era mRNA vaccine demand - its operating margin hit 41.8% in fiscal 2022 - and normalizing back from that is a headwind. Meanwhile, functional chemicals faced inventory drawdowns from cosmetics customers in late fiscal 2025, which pressured operating profit due to inventory adjustments by some customers for cosmetics-related products.

If revenue growth slows and capex stays high, the margin compression could drag on for longer than management expects. The payout ratio would creep higher, and the market could keep discounting the stock. The dividend wouldn't be at immediate risk at those leverage levels, but dividend growth could stall if EPS stays flat or declines.

That's the risk. But it's a growth execution risk, not a credit risk. The difference matters because credit risk is what forces dividend cuts.

Where It Fits in the Income Portfolio

NOF isn't a high-yield play. At current prices, the trailing dividend yield hovers around 2.19%, and the forward yield on ¥70 is closer to 2.51%. You wouldn't load up on this for yield alone.

The case is about dividend growth and reinvestment terms. A company that raised its dividend 36% in one year, is guiding another 15% increase, carries virtually no leverage, and is trading at a discount to its own historical valuation - that's a compounding income position, not a yield trap. If the income engine stays sound, the lower price means you can buy more future income on better terms. That's the reinvestment math.

For a diversified income portfolio, NOF would play a growth-and-income role. It doesn't replace the higher-yield anchors, but it adds a Japanese industrial name that's growing both revenue and payouts, with a balance sheet that would survive a stress scenario without touching the dividend.

The bottom line: The profit decline is a growth-investment bridge, not a credit event. The dividend is rising, well-covered, and backed by a fortress balance sheet. The stock's pullback is a reinvestment opportunity for patients who measure progress in income per share, not daily price action. The condition that would change this view is evidence that growth capex is failing to generate the revenue expansion management has guided - if sales growth falls materially short of that 23.7% target, the margin compression story becomes a concern worth reassessing.

Until then, the cash flow engine is intact, the payout is growing, and the entry terms are better than they were six months ago.